Dec 07, 2020 4:00pm EST Sutro Biopharma Announces Proposed Public Offering of 5 Million Shares of Common Stock
Dec 07, 2020 10:00am EST Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting
Dec 03, 2020 4:30pm EST Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
Dec 01, 2020 7:00am EST Sutro Biopharma Announces Appointment of Jon M. Wigginton, M.D., to Board of Directors
Nov 24, 2020 7:00am EST Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer
Nov 18, 2020 7:00am EST Sutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations
Nov 05, 2020 7:00am EST Sutro Biopharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights and Developments
Sep 09, 2020 4:01pm EDT Sutro Biopharma Presents Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer at the 2020 IGCS Annual Global Meeting
